Market OpportunityPositive feedback from key opinion leaders reinforces confidence in vutrisiran’s differentiated profile and the large commercial opportunity in ATTR-CM.
Revenue PotentialAmvuttra's peak sales estimate of ~$11.6B is considered conservative, indicating potential for higher revenue.
Treatment EfficacyVutrisiran treatment was associated with benefits versus placebo across multiple well-established clinical measures of disease progression, including 6-Minute Walk Test, Kansas City Cardiovascular Questionnaire, and NYHA Class.